Table 1.
Summary of mutation detection.
| Blood samples | Tumor samples | |||||
|---|---|---|---|---|---|---|
| Breast | Ovarian | |||||
| Screened | Mutations | Screened | Mutations | Screened | Mutations | |
| Exon 21 | 627 | 0 | 50 | 0 | 21 | 0 |
| Exon 22 | 627 | 0 | 50 | 0 | 21 | 0 |
| Exon 23 | 627 | 0 | 50 | 0 | 21 | 0 |
To detect heterozygous sequence changes, peripheral blood samples from breast and/or ovarian cancer patients were subjected to HRM analysis using primers specific to exons 21, 22 and 23. To detect potentially homozygous sequence changes from breast and ovarian tumor samples, PCR amplicons of these exons were directly sequenced.